Concepts (271)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Alzheimer Disease | 33 | 2024 | 1307 | 3.540 |
Why?
|
| Aging | 31 | 2023 | 1098 | 3.420 |
Why?
|
| Cognitive Dysfunction | 17 | 2024 | 727 | 2.360 |
Why?
|
| Cognition | 21 | 2024 | 941 | 1.750 |
Why?
|
| Hospitalization | 5 | 2019 | 290 | 1.650 |
Why?
|
| Aged, 80 and over | 55 | 2024 | 3754 | 1.650 |
Why?
|
| Dementia | 11 | 2024 | 388 | 1.650 |
Why?
|
| Health Literacy | 7 | 2018 | 84 | 1.430 |
Why?
|
| Aged | 60 | 2024 | 7498 | 1.330 |
Why?
|
| Independent Living | 12 | 2022 | 225 | 1.310 |
Why?
|
| Female | 62 | 2024 | 13059 | 1.150 |
Why?
|
| Male | 63 | 2024 | 12556 | 1.130 |
Why?
|
| Activities of Daily Living | 10 | 2022 | 355 | 1.120 |
Why?
|
| Brain | 16 | 2024 | 1200 | 0.980 |
Why?
|
| Cohort Studies | 21 | 2024 | 1425 | 0.970 |
Why?
|
| Humans | 77 | 2024 | 23169 | 0.970 |
Why?
|
| Decision Making | 12 | 2016 | 186 | 0.850 |
Why?
|
| Economics | 3 | 2018 | 12 | 0.790 |
Why?
|
| Longitudinal Studies | 18 | 2023 | 1048 | 0.760 |
Why?
|
| DNA-Binding Proteins | 5 | 2022 | 230 | 0.710 |
Why?
|
| Social Behavior | 2 | 2011 | 50 | 0.690 |
Why?
|
| Work | 1 | 2020 | 6 | 0.680 |
Why?
|
| Women | 1 | 2020 | 13 | 0.680 |
Why?
|
| TDP-43 Proteinopathies | 2 | 2021 | 83 | 0.620 |
Why?
|
| Cognition Disorders | 6 | 2016 | 688 | 0.610 |
Why?
|
| National Institute on Aging (U.S.) | 1 | 2019 | 10 | 0.600 |
Why?
|
| Emergencies | 1 | 2019 | 29 | 0.590 |
Why?
|
| Neuropsychological Tests | 15 | 2021 | 866 | 0.570 |
Why?
|
| Social Participation | 2 | 2022 | 10 | 0.540 |
Why?
|
| Biomarkers | 2 | 2020 | 476 | 0.530 |
Why?
|
| Interpersonal Relations | 3 | 2014 | 87 | 0.530 |
Why?
|
| Information Literacy | 2 | 2014 | 5 | 0.520 |
Why?
|
| Risk Assessment | 1 | 2019 | 552 | 0.510 |
Why?
|
| United States | 9 | 2024 | 1820 | 0.510 |
Why?
|
| Motor Activity | 3 | 2013 | 275 | 0.490 |
Why?
|
| Risk Reduction Behavior | 1 | 2015 | 36 | 0.450 |
Why?
|
| Delay Discounting | 1 | 2015 | 20 | 0.450 |
Why?
|
| Social Environment | 2 | 2011 | 67 | 0.440 |
Why?
|
| Trust | 1 | 2014 | 9 | 0.420 |
Why?
|
| Fraud | 1 | 2014 | 16 | 0.420 |
Why?
|
| Caregivers | 10 | 2008 | 185 | 0.420 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2020 | 154 | 0.410 |
Why?
|
| Mental Health | 2 | 2014 | 96 | 0.410 |
Why?
|
| Age Factors | 8 | 2020 | 639 | 0.410 |
Why?
|
| Medicare | 4 | 2024 | 107 | 0.380 |
Why?
|
| Educational Status | 6 | 2020 | 214 | 0.380 |
Why?
|
| Association | 1 | 2011 | 4 | 0.370 |
Why?
|
| Lewy Body Disease | 1 | 2012 | 70 | 0.360 |
Why?
|
| Cerebral Infarction | 1 | 2012 | 109 | 0.360 |
Why?
|
| Mobility Limitation | 2 | 2012 | 73 | 0.350 |
Why?
|
| Diet, Mediterranean | 2 | 2023 | 62 | 0.350 |
Why?
|
| Risk Factors | 10 | 2022 | 1988 | 0.340 |
Why?
|
| Risk | 4 | 2015 | 161 | 0.330 |
Why?
|
| Follow-Up Studies | 8 | 2019 | 1427 | 0.310 |
Why?
|
| Middle Aged | 19 | 2019 | 8000 | 0.310 |
Why?
|
| Loneliness | 3 | 2023 | 42 | 0.310 |
Why?
|
| Residence Characteristics | 5 | 2016 | 175 | 0.300 |
Why?
|
| Memory | 6 | 2018 | 211 | 0.300 |
Why?
|
| Prospective Studies | 6 | 2019 | 1512 | 0.290 |
Why?
|
| Apolipoprotein E4 | 4 | 2022 | 173 | 0.280 |
Why?
|
| Autopsy | 5 | 2021 | 257 | 0.280 |
Why?
|
| Sex Factors | 7 | 2020 | 389 | 0.280 |
Why?
|
| Brain Infarction | 2 | 2018 | 63 | 0.260 |
Why?
|
| Quality of Life | 3 | 2012 | 560 | 0.250 |
Why?
|
| Apolipoproteins E | 4 | 2023 | 142 | 0.250 |
Why?
|
| Proportional Hazards Models | 4 | 2016 | 274 | 0.240 |
Why?
|
| Mental Competency | 4 | 2008 | 9 | 0.240 |
Why?
|
| Chicago | 7 | 2021 | 816 | 0.230 |
Why?
|
| Social Isolation | 2 | 2023 | 19 | 0.230 |
Why?
|
| Mental Status and Dementia Tests | 3 | 2020 | 41 | 0.230 |
Why?
|
| Genotype | 2 | 2018 | 246 | 0.220 |
Why?
|
| Family | 2 | 2020 | 85 | 0.220 |
Why?
|
| Income | 3 | 2022 | 66 | 0.210 |
Why?
|
| Amyloid beta-Peptides | 5 | 2024 | 197 | 0.210 |
Why?
|
| Neuroimaging | 2 | 2021 | 102 | 0.200 |
Why?
|
| Psychiatric Status Rating Scales | 4 | 2016 | 267 | 0.190 |
Why?
|
| Disease Progression | 4 | 2020 | 523 | 0.180 |
Why?
|
| Brain Injuries, Traumatic | 1 | 2022 | 14 | 0.180 |
Why?
|
| Clinical Trials as Topic | 1 | 2002 | 196 | 0.180 |
Why?
|
| Depression | 3 | 2015 | 369 | 0.180 |
Why?
|
| Adaptation, Psychological | 1 | 2022 | 166 | 0.180 |
Why?
|
| Patient Participation | 4 | 2008 | 43 | 0.180 |
Why?
|
| Cross-Sectional Studies | 8 | 2022 | 774 | 0.170 |
Why?
|
| Politics | 3 | 2008 | 11 | 0.170 |
Why?
|
| Cognitive Reserve | 1 | 2021 | 22 | 0.170 |
Why?
|
| Financing, Personal | 3 | 2018 | 16 | 0.170 |
Why?
|
| Social Segregation | 1 | 2020 | 6 | 0.170 |
Why?
|
| Personality | 1 | 2021 | 43 | 0.170 |
Why?
|
| Brain Diseases | 1 | 2021 | 55 | 0.170 |
Why?
|
| Employment | 1 | 2020 | 40 | 0.170 |
Why?
|
| Arteriolosclerosis | 2 | 2021 | 57 | 0.160 |
Why?
|
| Socioeconomic Factors | 2 | 2018 | 270 | 0.160 |
Why?
|
| Memory Disorders | 1 | 2020 | 104 | 0.160 |
Why?
|
| Cognitive Aging | 1 | 2020 | 56 | 0.160 |
Why?
|
| Awareness | 1 | 2020 | 37 | 0.160 |
Why?
|
| Disability Evaluation | 2 | 2011 | 218 | 0.150 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2018 | 261 | 0.150 |
Why?
|
| Hospitals, Low-Volume | 1 | 2018 | 5 | 0.150 |
Why?
|
| Hospitals, High-Volume | 1 | 2018 | 7 | 0.150 |
Why?
|
| Nervous System Diseases | 1 | 2019 | 99 | 0.140 |
Why?
|
| Models, Neurological | 1 | 2018 | 21 | 0.140 |
Why?
|
| Research Subjects | 2 | 2008 | 9 | 0.140 |
Why?
|
| Neurofibrillary Tangles | 4 | 2022 | 119 | 0.140 |
Why?
|
| Immunocompromised Host | 1 | 2018 | 42 | 0.140 |
Why?
|
| Mutation | 1 | 2020 | 328 | 0.140 |
Why?
|
| Blood Glucose | 1 | 2018 | 99 | 0.140 |
Why?
|
| Neural Pathways | 1 | 2018 | 55 | 0.140 |
Why?
|
| White Matter | 2 | 2016 | 109 | 0.140 |
Why?
|
| Prevalence | 2 | 2012 | 384 | 0.140 |
Why?
|
| Regression Analysis | 2 | 2015 | 219 | 0.140 |
Why?
|
| Stress, Psychological | 2 | 2016 | 205 | 0.140 |
Why?
|
| Exercise | 1 | 2021 | 397 | 0.140 |
Why?
|
| Hospital Mortality | 1 | 2018 | 133 | 0.140 |
Why?
|
| Learning | 2 | 2016 | 62 | 0.140 |
Why?
|
| Adult | 6 | 2022 | 7031 | 0.130 |
Why?
|
| Cerebrovascular Disorders | 1 | 2018 | 99 | 0.130 |
Why?
|
| Sepsis | 1 | 2018 | 112 | 0.130 |
Why?
|
| Ambulatory Care | 1 | 2017 | 65 | 0.130 |
Why?
|
| Informed Consent | 2 | 2008 | 22 | 0.130 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2018 | 148 | 0.130 |
Why?
|
| RNA Splicing | 1 | 2016 | 6 | 0.120 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2016 | 9 | 0.120 |
Why?
|
| Incidence | 3 | 2016 | 635 | 0.120 |
Why?
|
| LDL-Receptor Related Proteins | 1 | 2016 | 9 | 0.120 |
Why?
|
| Intelligence | 1 | 2016 | 14 | 0.120 |
Why?
|
| Gray Matter | 1 | 2016 | 39 | 0.120 |
Why?
|
| Comprehension | 1 | 2016 | 25 | 0.120 |
Why?
|
| Interview, Psychological | 2 | 2008 | 39 | 0.120 |
Why?
|
| Alleles | 2 | 2018 | 163 | 0.120 |
Why?
|
| Time Factors | 3 | 2014 | 1275 | 0.120 |
Why?
|
| Chronic Disease | 1 | 2017 | 389 | 0.120 |
Why?
|
| Crime Victims | 1 | 2016 | 24 | 0.120 |
Why?
|
| Health Behavior | 2 | 2014 | 149 | 0.120 |
Why?
|
| Amyloid | 3 | 2021 | 39 | 0.120 |
Why?
|
| Psychological Tests | 1 | 2015 | 42 | 0.110 |
Why?
|
| Racism | 1 | 2015 | 26 | 0.110 |
Why?
|
| Poverty | 1 | 2015 | 92 | 0.110 |
Why?
|
| Minority Groups | 1 | 2015 | 67 | 0.110 |
Why?
|
| Music | 1 | 2014 | 19 | 0.110 |
Why?
|
| Neoplasms | 1 | 2017 | 219 | 0.110 |
Why?
|
| tau Proteins | 3 | 2022 | 144 | 0.110 |
Why?
|
| Multilingualism | 1 | 2014 | 20 | 0.110 |
Why?
|
| Parkinsonian Disorders | 1 | 2016 | 164 | 0.110 |
Why?
|
| Social Support | 2 | 2015 | 178 | 0.100 |
Why?
|
| Odds Ratio | 4 | 2018 | 224 | 0.100 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2014 | 168 | 0.100 |
Why?
|
| Disabled Persons | 1 | 2013 | 86 | 0.090 |
Why?
|
| Neprilysin | 1 | 2012 | 7 | 0.090 |
Why?
|
| Automobile Driving | 1 | 2012 | 17 | 0.090 |
Why?
|
| Actigraphy | 1 | 2012 | 80 | 0.090 |
Why?
|
| Lewy Bodies | 3 | 2018 | 147 | 0.090 |
Why?
|
| Muscle Strength | 1 | 2012 | 99 | 0.090 |
Why?
|
| Vascular Diseases | 1 | 2011 | 35 | 0.090 |
Why?
|
| Health Status | 2 | 2012 | 203 | 0.080 |
Why?
|
| Environmental Health | 1 | 2010 | 6 | 0.080 |
Why?
|
| Motor Skills Disorders | 1 | 2010 | 14 | 0.080 |
Why?
|
| Severity of Illness Index | 2 | 2005 | 811 | 0.080 |
Why?
|
| Lead Poisoning, Nervous System, Adult | 1 | 2010 | 1 | 0.080 |
Why?
|
| Lead | 1 | 2010 | 2 | 0.080 |
Why?
|
| Phobic Disorders | 1 | 2010 | 63 | 0.080 |
Why?
|
| Occupational Exposure | 1 | 2010 | 18 | 0.080 |
Why?
|
| Urban Population | 1 | 2011 | 132 | 0.080 |
Why?
|
| Occupational Diseases | 1 | 2010 | 22 | 0.080 |
Why?
|
| Body Mass Index | 1 | 2011 | 382 | 0.070 |
Why?
|
| Surveys and Questionnaires | 2 | 2021 | 1037 | 0.070 |
Why?
|
| Third-Party Consent | 1 | 2008 | 1 | 0.070 |
Why?
|
| Ethics, Research | 1 | 2008 | 3 | 0.070 |
Why?
|
| Assisted Living Facilities | 1 | 2008 | 6 | 0.070 |
Why?
|
| Attitude | 1 | 2008 | 31 | 0.070 |
Why?
|
| Health Services Needs and Demand | 1 | 2008 | 42 | 0.070 |
Why?
|
| Delivery of Health Care | 2 | 2015 | 125 | 0.070 |
Why?
|
| Nursing Homes | 1 | 2008 | 41 | 0.070 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2008 | 43 | 0.070 |
Why?
|
| Selegiline | 1 | 2005 | 2 | 0.060 |
Why?
|
| alpha-Tocopherol | 1 | 2005 | 11 | 0.060 |
Why?
|
| Case-Control Studies | 2 | 2018 | 481 | 0.060 |
Why?
|
| Mood Disorders | 1 | 2005 | 23 | 0.060 |
Why?
|
| Physician-Patient Relations | 1 | 2005 | 38 | 0.060 |
Why?
|
| Self Report | 2 | 2016 | 195 | 0.060 |
Why?
|
| Civil Rights | 1 | 2004 | 2 | 0.060 |
Why?
|
| Healthy Lifestyle | 1 | 2024 | 36 | 0.050 |
Why?
|
| Illinois | 2 | 2015 | 220 | 0.050 |
Why?
|
| Statistics as Topic | 2 | 2015 | 84 | 0.050 |
Why?
|
| Vitamins | 1 | 2022 | 14 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2021 | 875 | 0.050 |
Why?
|
| Vitamin D | 1 | 2022 | 28 | 0.050 |
Why?
|
| Unconsciousness | 1 | 2022 | 5 | 0.050 |
Why?
|
| Infarction | 1 | 2022 | 19 | 0.050 |
Why?
|
| Anthocyanins | 1 | 2022 | 5 | 0.050 |
Why?
|
| Sclerosis | 1 | 2022 | 56 | 0.050 |
Why?
|
| Fruit | 1 | 2022 | 25 | 0.050 |
Why?
|
| Logistic Models | 2 | 2018 | 357 | 0.040 |
Why?
|
| Motor Skills | 1 | 2021 | 37 | 0.040 |
Why?
|
| Individuality | 1 | 2021 | 12 | 0.040 |
Why?
|
| Neuroticism | 1 | 2021 | 21 | 0.040 |
Why?
|
| Southeastern United States | 1 | 2020 | 13 | 0.040 |
Why?
|
| Midwestern United States | 1 | 2020 | 47 | 0.040 |
Why?
|
| Religion | 1 | 2019 | 39 | 0.040 |
Why?
|
| Multilevel Analysis | 1 | 2018 | 5 | 0.040 |
Why?
|
| Heterozygote | 1 | 2018 | 89 | 0.040 |
Why?
|
| Hippocampus | 1 | 2020 | 200 | 0.040 |
Why?
|
| Neuropathology | 1 | 2018 | 60 | 0.030 |
Why?
|
| Critical Care | 1 | 2018 | 110 | 0.030 |
Why?
|
| Likelihood Functions | 1 | 2017 | 22 | 0.030 |
Why?
|
| Mental Status Schedule | 2 | 2008 | 66 | 0.030 |
Why?
|
| Plaque, Amyloid | 1 | 2017 | 86 | 0.030 |
Why?
|
| Length of Stay | 1 | 2018 | 305 | 0.030 |
Why?
|
| Vulnerable Populations | 1 | 2016 | 19 | 0.030 |
Why?
|
| Frontal Lobe | 1 | 2016 | 53 | 0.030 |
Why?
|
| Anisotropy | 1 | 2016 | 35 | 0.030 |
Why?
|
| Temporal Lobe | 1 | 2016 | 63 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 2016 | 56 | 0.030 |
Why?
|
| Diagnosis | 1 | 2015 | 16 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2016 | 176 | 0.030 |
Why?
|
| Memory, Episodic | 1 | 2016 | 74 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2016 | 138 | 0.030 |
Why?
|
| Epidemiologic Methods | 1 | 2015 | 16 | 0.030 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2016 | 88 | 0.030 |
Why?
|
| Demography | 1 | 2015 | 58 | 0.030 |
Why?
|
| Cities | 1 | 2015 | 13 | 0.030 |
Why?
|
| Financial Management | 1 | 2015 | 18 | 0.030 |
Why?
|
| Life Change Events | 1 | 2014 | 33 | 0.030 |
Why?
|
| Empathy | 1 | 2014 | 32 | 0.030 |
Why?
|
| Mental Recall | 1 | 2014 | 47 | 0.030 |
Why?
|
| Language | 1 | 2014 | 58 | 0.030 |
Why?
|
| Spouses | 2 | 2005 | 30 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2016 | 517 | 0.030 |
Why?
|
| Spatial Behavior | 1 | 2012 | 5 | 0.020 |
Why?
|
| Licensure | 1 | 2012 | 6 | 0.020 |
Why?
|
| Accidents, Traffic | 1 | 2012 | 19 | 0.020 |
Why?
|
| Mice | 1 | 2016 | 1232 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2012 | 19 | 0.020 |
Why?
|
| Cell Line, Transformed | 1 | 2012 | 13 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2012 | 19 | 0.020 |
Why?
|
| Environment | 1 | 2012 | 38 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2012 | 50 | 0.020 |
Why?
|
| Transfection | 1 | 2012 | 119 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2012 | 234 | 0.020 |
Why?
|
| Linear Models | 1 | 2012 | 192 | 0.020 |
Why?
|
| Baltimore | 1 | 2011 | 8 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2012 | 281 | 0.020 |
Why?
|
| Reaction Time | 1 | 2011 | 78 | 0.020 |
Why?
|
| Data Collection | 1 | 2011 | 83 | 0.020 |
Why?
|
| Executive Function | 1 | 2011 | 87 | 0.020 |
Why?
|
| Psychometrics | 1 | 2011 | 177 | 0.020 |
Why?
|
| Brain Chemistry | 1 | 2010 | 33 | 0.020 |
Why?
|
| Organ Size | 1 | 2010 | 84 | 0.020 |
Why?
|
| Psychomotor Performance | 1 | 2011 | 155 | 0.020 |
Why?
|
| Survival Rate | 1 | 2010 | 323 | 0.020 |
Why?
|
| Animals | 1 | 2016 | 3272 | 0.020 |
Why?
|
| Tibia | 1 | 2010 | 192 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2016 | 2971 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2008 | 88 | 0.020 |
Why?
|
| Observer Variation | 1 | 2008 | 85 | 0.020 |
Why?
|
| Simvastatin | 1 | 2008 | 12 | 0.020 |
Why?
|
| ROC Curve | 1 | 2008 | 124 | 0.020 |
Why?
|
| Prognosis | 1 | 2010 | 740 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2008 | 250 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2008 | 449 | 0.020 |
Why?
|
| Professional-Family Relations | 1 | 2005 | 17 | 0.010 |
Why?
|
| Cost of Illness | 1 | 2005 | 43 | 0.010 |
Why?
|
| Judgment | 1 | 2005 | 4 | 0.010 |
Why?
|
| Nootropic Agents | 1 | 2005 | 11 | 0.010 |
Why?
|
| Policy Making | 1 | 2004 | 12 | 0.010 |
Why?
|
| Long-Term Care | 1 | 2004 | 56 | 0.010 |
Why?
|
| Patient Compliance | 1 | 2005 | 145 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2003 | 125 | 0.010 |
Why?
|
| Interviews as Topic | 1 | 2003 | 116 | 0.010 |
Why?
|
| Pennsylvania | 1 | 2002 | 6 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2002 | 75 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2003 | 592 | 0.010 |
Why?
|